Peer reviewed
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-5)
Phase 3 trial comparing tirzepatide to semaglutide as add-on therapy in Type 2 diabetes, demonstrating greater A1C and weight reductions with tirzepatide.
New England Journal of MedicinePublished Feb 1, 2023Accessed Jul 8, 2026
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-tirzepatide-surpass5-2023
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.